Abstract:Background Diagnosis of colorectal cancer (CRC) during early stages can greatly improve patient outcome. Although technical advances in the field of genomics and proteomics have identified a number of candidate biomarkers for non-invasive screening and diagnosis, developing more sensitive and specific methods with improved cost-effectiveness and patient compliance has tremendous potential to help combat the disease. Methods We enrolled three cohorts of 479 subjects, including 226 CRC cases, 197 healthy controls, and 56 advanced precancerous lesions (APC). In the discovery cohort, we used quantitative mass spectrometry to measure the expression profile of plasma proteins and applied machine-learning to select candidate proteins. We then developed a targeted mass spectrometry assay to measure plasma concentrations of seven proteins and a logistic regression classifier to distinguish CRC from healthy subjects. The classifier was further validated using two independent cohorts. Results The seven-protein panel consisted of leucine rich alpha-2-glycoprotein 1 (LRG1), complement C9 (C9), insulin-like growth factor binding protein 2 (IGFBP2), carnosine dipeptidase 1 (CNDP1), inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3), serpin family A member 1 (SERPINA1), and alpha-1-acid glycoprotein 1 (ORM1). The panel classified CRC and healthy subjects with high accuracy, since the area under curve (AUC) of the training and testing cohort reached 0.954 and 0.958. The AUC of the two independent validation cohorts was 0.905 and 0.909. In one validation cohort, the panel had an overall sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 89.9%, 81.8%, 89.2%, and 82.9%, respectively. In another blinded validation cohort, the panel classified CRC from healthy subjects with a sensitivity of 81.5%, specificity of 97.9%, and overall accuracy of 92.0%. Finally, the panel was able to detect APC with a sensitivity of 49%. Conclusions This seven-protein classifier is a clear improvement compared to previously published blood-based protein biomarkers for detecting early-stage CRC, and is of translational potential to develop into a clinically useful assay.

Diagnostic Proteomics: Serum Proteomic Patterns for the Detection of Early Stage Cancers.

Proteomic Diagnosis Models from Serum for Early Detection of Oral Squamous Cell Carcinoma.

Use of Serological Proteomic Methods to Find Biomarkers Associated with Breast Cancer

Clinical proteomics and mass spectrometry profiling for cancer detection

Efficient Cancer Biomarker Screening and Multicancer Detection Enabled by a Multidimensional Serum Proteomic Strategy.

Cancer Serum Atlas-Supported Precise Pan-Targeted Proteomics Enable Multicancer Detection

Clinical Application of Serum-Based Proteomics Technology in Human Tumor Research.

Quantitative Proteomics and Biomarker Discovery in Human Cancer

Diagnostic and Prognostic Application of Proteomic Patterns in Breast Cancer

A Serum Proteomic Pattern for the Detection of Colorectal Adenocarcinoma Using Surface Enhanced Laser Desorption and Ionization Mass Spectrometry

Proteomics in prostate cancer biomarker discovery

Data mining techniques for cancer detection using serum proteomic profiling.

A Proteomic Classifier Panel for Early Screening of Colorectal Cancer: a Case Control Study

Recent Advances in Proteomics and Cancer Biomarker Discovery

Tissue and Plasma Proteomics for Early Stage Cancer Detection

Protein microarrays and quantum dot probes for early cancer detection.

Proteomics techniques in protein biomarker discovery

Diagnostic Application of Serum Protein Pattern and Artificial Neural Network Software in Breast Cancer

Pan‐targeted Quantification of Deep and Comprehensive Cancer Serum Proteome Improves Cancer Detection

Mass Spectrometry-Assisted Gel-Based Proteomics In Cancer Biomarker Discovery: Approaches And Application

Clinical potential of proteomics in the diagnosis of ovarian cancer